特别关注｜PD-1/PD-L1在肝细胞癌治疗中的应用(10)

参考文献：
[1]Bureau of Medical Administration, National Health Commission of the People"s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
[2]PARDOLL DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264. DOI: 10.1038/nrc3239
[3]EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2
[4]CROCENZI TS, EL-KHOUEIRY AB, YAU T, et al. Nivolumab in sorafenib-naive and-experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study[J]. J Clin Oncol, 2017, 35(15 Suppl): 4013.